Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement




Aug
11
Today In Oncology
Global Survey Identifies Barriers to Integrative Oncology Use in Cancer Care
AI Biomarker May Guide Adjuvant Chemotherapy in Resected Pancreatic Cancer
First-in-Class Bispecific ADC Shows Activity in Relapsed Extensive-Stage Small Cell Lung Cancer
NIH-Funded International Research Yields Patient-Derived Tumor Compendium
Stanford Appoints New Leader to Expand Impact in Early Drug Development
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo